The researchers enrolled 842 consecutive symptomatic adults referred for upper gastrointestinal endoscopy. They collected sociodemographic, behavioral, clinical and endoscopic information through a standardized questionnaire and compared enzyme-linked immunosorbent assay (ELISA) and rapid urease testing with histopathological examination using hematoxylin and eosin staining. Histology served as the diagnostic gold standard, while logistic regression was used to identify factors independently associated with infection. Epigastric pain was the most common indication for endoscopy, reported in 59.9% of participants. Erosive lesions or ulcerations were the predominant endoscopic findings in 28.4%, and inflammatory lesions were documented in 22.3%.

ELISA showed sensitivity of 99.7%, specificity of 100.0% and diagnostic accuracy of 99.8% against histology, with almost perfect agreement (κ = 0.994). The rapid urease test had sensitivity of 88.3%, specificity of 88.5% and diagnostic accuracy of 88.4%, representing substantial agreement with histology (κ = 0.722). Infection was present in all patients with gastric tumors, 91.2% of those with active duodenal ulcers and 82.1% of those with active gastric ulcers.

Logistic regression identified several demographic, clinical and behavioral factors independently associated with infection. These included younger age, defined in the abstract as 15–32 years (adjusted odds ratio, 2.88); living in households with five members (9.83); blood group O (2.25); vomiting (12.60); investigation for anemia (16.38); and absence of medication use (4.33). These were associations in the study population and do not establish causation.

The results apply to symptomatic patients referred for endoscopy at two tertiary hospitals in Douala, not to the broader population of the city or Cameroon. Because the study was cross-sectional, it cannot determine whether the reported factors preceded infection or changes over time. The supplied evidence is an abstract from an early open-access version of the article, which states that further editorial changes may follow; confidence intervals and other detailed measures of uncertainty were not provided in the abstract.

Subject of Research: Cross-sectional assessment of H. pylori prevalence and diagnostic test performance among symptomatic adults undergoing endoscopy in Douala, Cameroon

Article Title: High prevalence and endoscopic patterns of Helicobacter pylori Infection among symptomatic adults in Douala, Cameroon: sociodemographic and behavioral correlates

Article References: Eyoum, B. B. B., Eloumou, F. S. B., Medi, C. S., Ekwala, J. R. M. N., Ntonga, C. L., Malongue, A., Fotso, C., Fotsing, S., Kamdem, C., Ateba, R. G., Kouitcheu, B. L. M., & Kuiate, J.-R. (2026). High prevalence and endoscopic patterns of Helicobacter pylori Infection among symptomatic adults in Douala, Cameroon: sociodemographic and behavioral correlates. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14451-8

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14451-8

Keywords: Helicobacter pylori, Douala, Cameroon, cross-sectional study, endoscopy, histology, ELISA, rapid urease test, prevalence, endoscopic findings, High, endoscopic

Performance in the training set was strong: the area under the curve was 0.92, with a 95% confidence interval of 0.86–0.96, while sensitivity reached 87.3% at 85.7% specificity. The independent validation set yielded an area under the curve of 0.95, with a 95% confidence interval of 0.91–0.97. At the fixed cutoff, sensitivity was 93.2% and specificity was 85%.

The investigators also performed internal validation through bootstrapping and Monte Carlo cross-validation, reporting that the assay’s discriminatory power remained robust under statistical resampling. These subgroup observations were derived from the retrospective study population, and the supplied results do not provide separate performance estimates for each subgroup. The study therefore supports the feasibility of BF-09 as a candidate blood-based marker, but it does not establish performance in a prospective screening population or show that use of the assay improves clinical outcomes.

Mammography is the standard-of-care screening method for breast cancer, although the paper identifies tissue density and overdiagnosis of benign conditions among its limitations and notes growing interest in alternative blood-based tests. Against that background, the findings offer preliminary support for BF-09 as a possible alternative screening assay rather than a validated replacement for established screening. Additional prospective evaluation would be needed to determine how the test performs when used in the intended screening setting.

The authors characterized BF-09 as having high potential as an alternative breast cancer screening test, based on the reported retrospective diagnostic performance and internal statistical validation.

Subject of Research: Retrospective evaluation of serum BF-09 for breast cancer detection.

Article Title: Diagnostic potential of serum BF-09 biomarker (protein SGF29) for early detection of breast cancer: high performance for early-stage cancer and major histological or molecular subtypes

Article References: Chavany, C., Dea, J., Valle, R. P. C., González, R. H., & Jendoubi, M. (2026). Diagnostic potential of serum BF-09 biomarker (protein SGF29) for early detection of breast cancer: high performance for early-stage cancer and major histological or molecular subtypes. Journal of Cancer Research and Clinical Oncology. https://doi.org/10.1007/s00432-026-06634-2

Image Credits: AI Generated

DOI: 10.1007/s00432-026-06634-2

Keywords: breast cancer, BF-09, SGF29, blood biomarker, ELISA, diagnostic accuracy, cancer screening, retrospective study, early detection, mammography, Diagnostic, potential

Non-suicidal self-injury is defined as the deliberate, repetitive destruction of body tissue, such as cutting, burning, or hitting oneself, without any intent to die. It is distressingly common in adolescence, and it frequently co-occurs with depressive disorders, where it can be difficult to distinguish from the emotional turmoil of the illness itself. Because young people often conceal self-injurious behavior out of shame or fear of parental reaction, clinicians rely heavily on screening instruments and careful questioning, and the behavior can go unnoticed until it escalates. The researchers behind the new study set out to ask whether the biology of depression with self-injury might differ measurably from the biology of depression alone, and whether a blood-borne signal could capture that difference.

Their candidate was nesfatin-1, an 82-amino-acid peptide derived from a larger precursor protein called nucleobindin-2, or NUCB2. First identified about two decades ago in the hypothalamus, the brain region that coordinates hunger, satiety, and the body’s stress response, nesfatin-1 powerfully suppresses food intake, which is why it is described as anorexigenic. But the peptide is not confined to feeding circuits. It is expressed in brain areas governing emotion and autonomic regulation, it interacts with the hypothalamic-pituitary-adrenal axis, the central stress machinery of the body, and it appears to modulate endogenous opioid and corticotropin-releasing hormone systems, both of which have been linked to emotional pain and self-harm. Elevated nesfatin-1 has previously been reported in panic disorder, generalized anxiety, and major depression, making it a plausible player in stress-related psychopathology.

To test the hypothesis, the team enrolled three groups of adolescents aged 12 to 18. The first comprised 40 young people diagnosed with major depressive disorder, the second comprised 41 adolescents with major depressive disorder and comorbid non-suicidal self-injury, and the third comprised 45 healthy controls. Crucially, all participants had been free of psychiatric medication for at least eight weeks before enrollment, removing a common confound in biomarker studies, since many antidepressants and other drugs can alter peptide levels. Diagnoses were established with the Schedule for Affective Disorders and Schizophrenia for School-Age Children, Present and Lifetime Version, a structured interview considered a gold standard in child psychiatry research. Depressive symptom severity was quantified with the Children’s Depression Inventory, while self-injurious behaviors were assessed with the Inventory of Statements About Self-Injury, an instrument designed specifically to characterize NSSI.

Serum nesfatin-1 concentrations were measured using a sandwich enzyme-linked immunosorbent assay, a laboratory technique in which antibodies capture the peptide from a blood sample and a second detection antibody generates a measurable signal proportional to the amount present. The results were striking. Nesfatin-1 levels differed significantly across the three groups, with the highest concentrations found in the adolescents who had both depression and self-injury. Both patient groups showed significantly higher levels than the healthy controls, but the self-injuring group also exceeded the non-self-injuring depressed group, a difference that reached statistical significance at p equals 0.010. What makes this particularly notable is that the two patient groups were clinically comparable: their Children’s Depression Inventory scores did not differ significantly, even though both were substantially higher than those of controls.

In other words, nesfatin-1 appeared to track something beyond the severity of depressive symptoms. Across the participants, serum levels correlated positively and strongly with depressive symptom severity, with a Spearman correlation coefficient of 0.691 and a p value below 0.001, indicating that the peptide rises with the depth of the depression. Yet when the researchers compared two groups of equally depressed adolescents, the presence of self-injury was associated with an additional elevation in the peptide. This pattern suggests that nesfatin-1 may reflect neurobiological processes tied specifically to self-injurious behavior, rather than simply serving as a proxy for how depressed a teenager feels on a questionnaire.

The team also examined how well the biomarker performed as a diagnostic discriminator using receiver operating characteristic, or ROC, curve analysis, a statistical method that plots sensitivity against specificity across all possible cutoff values and summarizes the result as the area under the curve, or AUC. An AUC of 1.0 indicates perfect discrimination, while 0.5 indicates performance no better than chance. Nesfatin-1 showed good discriminative ability for separating both patient groups from healthy controls. For the more demanding task of distinguishing adolescents with depression and self-injury from those with depression alone, performance was fair, with an AUC of 0.671 and a 95 percent confidence interval of 0.553 to 0.789, and a p value of 0.008. That is far from a definitive clinical test, but it is a meaningful signal for a single circulating molecule in a behavior as complex as self-harm.

Why might a satiety peptide be elevated in teenagers who hurt themselves? The authors point to nesfatin-1’s extensive connections with the body’s stress systems. The peptide interacts with corticotropin-releasing hormone signaling and with the endogenous opioid system, both of which are deeply involved in how the brain processes emotional distress. Self-injury is often described by those who engage in it as a way of regulating unbearable emotional states, and dysregulation of stress and pain-modulating circuits is thought to underlie that coping mechanism. Elevated nesfatin-1 could plausibly mark a state of heightened stress-system activation in which self-harm becomes more likely, although the cross-sectional design of the study means the direction of the relationship cannot be determined. It remains possible that the behavior itself, or the chronic distress surrounding it, drives peptide levels upward rather than the other way around.

The study’s limitations are those typical of pioneering biomarker work. The sample, while carefully characterized, is modest in size, and the cross-sectional design captures a single moment in time rather than tracking how nesfatin-1 changes as adolescents recover, relapse, or begin or stop self-injuring. The researchers themselves emphasize that future longitudinal studies with larger samples are needed to clarify the role and clinical relevance of the peptide in adolescents with depression and self-injury. Body mass index and metabolic factors, which can influence nesfatin-1 because of its appetite-related functions, are additional variables that larger studies will need to control more exhaustively. No one should expect a nesfatin-1 blood test in the clinic tomorrow.

Nevertheless, the findings add to a growing appreciation that self-injurious behavior in adolescent depression has measurable biological correlates, and they identify a candidate marker that is inexpensive to measure with standard laboratory equipment. If longitudinal research confirms that nesfatin-1 rises before or alongside the onset of self-harm, it could eventually help clinicians flag high-risk patients earlier, complementing psychological screening with an objective physiological signal. For now, the study offers something scientifically valuable in its own right: evidence that the boundary between metabolism and mood runs through molecules like nesfatin-1, and that the hypothalamus, that small cluster of neurons at the base of the brain, may hold clues to one of the most painful and hidden behaviors of adolescence. The research was funded by the Giresun University Scientific Research Projects Coordination Unit and conducted with ethics approval and informed consent from participants and their guardians.

Subject of Research: Serum nesfatin-1 levels as a biomarker associated with non-suicidal self-injury in adolescents with major depressive disorder

Article Title: Nesfatin-1 levels and non-suicidal self-injury in adolescents with major depressive disorder: a cross-sectional study

Article References: Onal, B. S., Arslan, H. F., Cobanoglu Osmanlı, C., Sahin, B., & Yitik Tonkaz, G. (2026). Nesfatin-1 levels and non-suicidal self-injury in adolescents with major depressive disorder: a cross-sectional study. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08612-x

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08612-x

Keywords: nesfatin-1, non-suicidal self-injury, major depressive disorder, adolescents, biomarker, BMC Psychiatry, hypothalamus, stress response, ELISA, ROC analysis, child and adolescent psychiatry, neurobiology

The research team focused on two economically significant pathogens of fruit crops: Capillovirus mali, the filamentous virus better known in the literature as apple stem grooving virus, and Ilarvirus ApMV, apple mosaic virus, an icosahedral member of a genus that includes several serious Prunus and hop viruses. Both are typically managed by excluding or removing infected planting material, which makes reliable, affordable detection during certification and quarantine testing a practical necessity rather than a laboratory luxury. The investigators set out to determine whether a computational pass over the viruses’ coat proteins could identify peptide epitopes that would yield polyclonal sera with genuinely improved diagnostic behavior.

Their starting point was AlphaFold3, the latest generation of deep-learning structure prediction, which they used to model the coat proteins of the target viruses. A three-dimensional prediction alone, however, is not a diagnostic recipe. The team therefore layered on a series of filters drawn from structural biology: predicted surface accessibility, so that a synthetic peptide would mimic a region an antibody could actually reach on the intact virion; physicochemical properties such as hydrophilicity, charge and flexibility, which influence whether a short linear fragment folds into something immunologically recognizable; and predicted RNA-protein interaction regions, which the authors deliberately considered when prioritizing candidate epitope stretches. By scoring candidate regions across these criteria, the pipeline narrowed a long protein down to a handful of short peptides worth synthesizing.

That filtering logic was tested against a broader comparative analysis spanning filamentous and icosahedral viruses, an unusual and valuable feature of the work. Rather than tuning the approach to a single pathogen, the authors looked for features that separated successful epitopes from unsuccessful ones across different virion architectures. The consistent signal was that accessibility and flexibility-associated properties tracked with immunodiagnostic performance, giving the field a transferable framework: before ordering a peptide, a diagnostic developer can interrogate a predicted structure and ask whether the chosen stretch is exposed, mobile and chemically disposed to raise clean antibodies.

The experimental half of the study put those computational picks to the test. Selected peptides were synthesized, conjugated and used to immunize animals, generating epitope-specific polyclonal antibodies at a fraction of the cost of hybridoma-based monoclonal production. The critical benchmark was a head-to-head comparison against conventional antisera raised against full-length viral coat proteins, which the authors obtained from Dr. Vipin Hallan, Chief Scientist at CSIR-IHBT in Palampur. In enzyme-linked immunosorbent assays, the peptide-derived antibodies showed improved specificity and reduced background reactivity compared with the full-length coat protein antisera, addressing the classic weakness of polyclonal reagents.

Peptide-competition ELISA provided mechanistic confirmation that the new sera were binding the intended epitopes: pre-absorbing the antibodies with the free peptide abolished or sharply reduced their signal, the expected signature of epitope-directed reactivity rather than incidental binding to contaminating or host proteins. The authors then validated the diagnostic claims across an orthogonal panel of methods. Reverse transcription polymerase chain reaction served as the molecular reference standard, while dot immunobinding assays and western blotting confirmed that the antibodies recognized the viral coat protein in infected material under multiple assay formats, not just under the particular chemistry of one plate-based test.

Perhaps the most deployment-relevant result came when the epitope-specific antibodies were incorporated into lateral flow immunoassays, the dipstick-style tests that dominate on-site plant diagnostics because they require no equipment or electricity. In that format, the peptide-derived reagents produced clearer test line signals and supported target-specific detection, exactly the property that separates a usable field test from an ambiguous one. For certification labs and inspection services that screen thousands of budwood samples and nursery trees, a reagent that cuts background without inflating cost could translate directly into fewer repeat tests and fewer false alarms during the short windows when planting material moves.

The commercial significance of the work is underscored by intellectual property activity: Maharishi Markandeshwar (Deemed to be University), with Sunny Dhir, Yashika Walia and Gourav Vats listed as inventors, has filed a patent application, number 202611076208, covering the three epitope sequences described in the study, two from the capillovirus and one from apple mosaic virus. The authors state no other competing financial or non-financial interests. The research was supported by the Sree Padmavathi Venkateswara Foundation through its Agricultural Research Award project and by the university’s Advanced Center for Climate Resilience and Crop Protection, a pairing that reflects a growing trend of regional foundations funding applied plant health technology in South Asia.

Methodologically, the study arrives at a moment when structure prediction has become routine but its application to immunodiagnostics, particularly in plant pathology, remains immature. Antibody development against plant viruses has historically relied on empirical choices: express the whole coat protein, purify it, immunize, and hope the resulting serum discriminates between the target and its relatives. The AlphaFold3-guided pipeline replaces that gamble with a ranked shortlist grounded in predicted exposure and flexibility, and the comparative analysis across virion shapes suggests the ranking criteria generalize beyond a single taxonomy. The authors are careful in their framing, noting that predicted structural accessibility and physicochemical properties may contribute to immunodiagnostic performance rather than guaranteeing it, an appropriately measured claim given that antibody quality also depends on carrier conjugation, adjuvant scheduling and animal responses that no structure model captures.

The practical implications extend across the plant health pipeline. Certification schemes for apple and other fruit propagation material depend on layered testing, and reagents that combine polyclonal economics with near-monoclonal discrimination fit neatly into existing ELISA and lateral flow workflows without new instrumentation. The framework also offers a template for emerging pathogens, where a diagnostic response often cannot wait for monoclonal development pipelines; a predicted structure and a short peptide order can compress the reagent timeline from months to weeks. As the authors conclude, structure-guided peptide selection offers a rational, low-cost route to precision plant virus immunodiagnostics, and the convergence of clear ELISA performance, validated molecular agreement and sharper field-format signals suggests the approach is ready to move from proof of concept into the diagnostic catalogs that growers and inspectors actually use.

Subject of Research: Structure-guided peptide epitope selection for developing specific, low-cost polyclonal antibody diagnostics against plant viruses

Article Title: Structure-guided epitope engineering enables precision plant virus immunodiagnostics

Article References: Vats, G., Saini, A., Devi, N., Singh, P., Tushir, N., Kumar R, S., Kaushal, A., Walia, Y., & Dhir, S. (2026). Structure-guided epitope engineering enables precision plant virus immunodiagnostics. npj Viruses. https://doi.org/10.1038/s44298-026-00251-z

Image Credits: AI Generated

DOI: 10.1038/s44298-026-00251-z

Keywords: plant viruses, epitope engineering, AlphaFold3, polyclonal antibodies, ELISA, lateral flow immunoassay, Capillovirus mali, apple mosaic virus, coat protein, immunodiagnostics, protein structure prediction, agricultural diagnostics

The study, published in Frontiers in Oncology by Lizhen Zhu of Qinghai University Affiliated Hospital and colleagues at Beijing Tsinghua Changgung Hospital, focused on a circulating molecule called soluble programmed death-1, or sPD-1. Unlike the membrane-bound PD-1 receptor that checkpoint inhibitors block, sPD-1 is a free-floating isoform generated by proteolytic cleavage or alternative splicing. It is thought to reflect peripheral T-cell activation, and previous work has tied it to prognosis in several solid tumors, though results have varied widely by tumor type, regimen, and assay. Whether it meant anything for patients heading into transplantation after immunotherapy was unknown.

To find out, the team measured pretransplant plasma sPD-1 and soluble PD-L1 with validated enzyme-linked immunosorbent assays in 105 liver transplant recipients with hepatocellular carcinoma. Fifty-one had received immune checkpoint inhibitors before surgery, while 54 had not, including 18 who went straight to transplant and 36 who received non-immunotherapy bridging treatment. Blood was drawn one day before transplantation, processed by centrifugation, stored at minus 80 degrees Celsius in a centralized biobank, and assayed in duplicate by laboratory staff blinded to clinical outcomes. The primary endpoint was two-year recurrence-free survival.

The numbers were striking. Patients treated with checkpoint inhibitors had markedly higher pretransplant sPD-1 than those without such exposure, a difference that was highly significant. Within the immunotherapy group itself, the pattern became even more consequential: the 21 patients whose cancer returned after transplantation had far higher sPD-1 concentrations than the 30 who stayed recurrence-free, while soluble PD-L1 showed no such separation. Using an exploratory cutoff of 2,073 picograms per milliliter, derived from the study cohort itself with a receiver operating characteristic analysis, high sPD-1 was associated with a two-year recurrence-free survival of just 7.7 percent, compared with 76.3 percent among patients below the threshold.

Statistical modeling reinforced the signal. Analyzed as a continuous variable, each doubling of pretransplant sPD-1 was associated with a 51 percent increase in the hazard of recurrence in unadjusted Cox regression. Crucially, the association survived adjustment for alpha-fetoprotein, the standard tumor marker, as well as tumor number and maximum tumor diameter, with an adjusted hazard ratio of 1.51. In separate multivariable analysis, both AFP and sPD-1 remained independently linked to recurrence, and a parsimonious model combining the two achieved an optimism-corrected concordance index of 0.736 after bootstrap validation, suggesting modest but real discriminative ability.

Perhaps most intriguing was where the signal appeared. The association held among patients whose scans showed a response by modified RECIST criteria, among patients whose explanted livers showed no microvascular invasion, and among patients with AFP at or below 400 nanograms per milliliter, the conventional low-risk threshold. In that final subgroup, high sPD-1 still stratified survival, with a hazard ratio of 4.15. The implication is that soluble PD-1 may capture systemic immune information that standard tumor-burden measures, radiological response, and pathology all miss, offering a glimpse of residual risk that the existing toolkit cannot see.

The investigators also probed whether the marker was simply an artifact of treatment timing. Neither the number of immunotherapy cycles nor the interval between the last drug dose and blood sampling, which had a median of 65.5 days, correlated significantly with sPD-1 levels. Acute cellular rejection, the safety concern that has dominated prior studies of immunotherapy before transplantation, occurred in 15.7 percent of the immunotherapy group and was managed successfully in every case, and sPD-1 showed no association with rejection episodes.

Still, the authors are careful about scope. The study is a single-center retrospective cohort with only 21 recurrence events in the immunotherapy group, the cutoff was derived and tested in the same patients, and microvascular invasion could only be assessed after surgery. Formal mechanistic work, including immune-cell profiling and tumor immunophenotyping, was outside its reach, and the researchers cannot rule out assay interference from residual therapeutic antibodies, a known hazard when measuring soluble checkpoint molecules in treated patients. They recommend future studies incorporate drug-specific interference testing and standardized sampling windows.

Those caveats notwithstanding, the work signals a shift in how clinicians think about immunotherapy before liver transplantation. The conversation has moved beyond allograft safety toward predicting tumor recurrence, and a plasma biomarker drawn the day before surgery fits neatly into that vision. Soluble PD-1 is not ready for the clinic, the authors stress, and independent validation in larger external cohorts is required. But if the finding holds, a routine blood test could soon help decide which patients getting checkpoint inhibitors before a new liver are truly cured, and which need closer surveillance after the operation.

Subject of Research: Soluble PD-1 as a pretransplant biomarker predicting recurrence after liver transplantation in immunotherapy-treated hepatocellular carcinoma

Article Title: Pretransplant plasma soluble PD-1 and recurrence after liver transplantation in ICI-treated hepatocellular carcinoma: an exploratory biomarker study

Article References: Zhu, L., Wang, R., Shu, W., Gao, Y., Zhang, G., Zhao, W., Hou, Y., & Lu, Q. (2026). Pretransplant plasma soluble PD-1 and recurrence after liver transplantation in ICI-treated hepatocellular carcinoma: an exploratory biomarker study. Frontiers in Oncology, 16, Article 1944586. https://doi.org/10.3389/fonc.2026.1944586

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1944586

Keywords: hepatocellular carcinoma, liver transplantation, immune checkpoint inhibitors, soluble PD-1, biomarker, cancer recurrence, AFP, microvascular invasion, recurrence-free survival, ELISA, transplant oncology, prognosis

MMPs are a family of 23 zinc- and calcium-dependent proteolytic enzymes in humans that degrade the extracellular matrix (ECM) — the structural scaffold of collagen, fibronectin, elastin, and laminin that confines cells within tissues. When tumor cells or stromal cells in the tumor microenvironment upregulate MMP expression, they weaken the basement membrane, liberate growth factors, and create physical space for tumor expansion, migration, and intravasation into lymphatic vessels. This is the molecular machinery of invasion and metastasis. In OSCC specifically, cancer-associated fibroblasts, inflammatory cells, and endothelial cells secrete cytokines such as tumor necrosis factor-alpha and interleukins, along with growth factors like EGF and TGF-beta, which upregulate MMP gene expression and accelerate oral tumorigenesis. Despite decades of research on individual MMPs like MMP-2 and MMP-9, no study had systematically evaluated the collective influence of all 23 human MMPs on OSCC progression — until now.

The team, led by P. Sakthi Subhashini and supervised by S. Asha Devi at VIT, along with surgical oncologists T. Bharanidharan and D. Suresh Kumar, retrieved gene expression data from 12 microarray datasets in the NCBI Gene Expression Omnibus (GEO) and supplemented this with RNA-seq data from 258 OSCC tumor samples and 18 normal controls in The Cancer Genome Atlas (TCGA). Using the limma and edgeR R packages, they identified differentially expressed genes (DEGs) with a fold change greater than 2 and an adjusted p-value below 0.05. Batch effects across multiple microarray platforms were corrected using the SVA package. From this integrated transcriptomic landscape, six MMP family members emerged as consistently upregulated in OSCC tumor tissue: MMP-1, MMP-10, MMP-3, MMP-12, MMP-13, and MMP-9. Notably, MMP-1 was upregulated in all 13 datasets, followed by MMP-10 and MMP-3 in 12 datasets each, MMP-12 in 11, MMP-13 in 8, and MMP-9 in 7.

To understand what these enzymes are doing biologically, the researchers performed Gene Set Enrichment Analysis (GSEA) on TCGA tumor samples stratified by an MMP-based risk score. The results were striking: rather than pointing primarily at core signaling cascades, the analysis revealed that upregulated MMPs are deeply intertwined with metabolic reprogramming — a key emerging cancer hallmark. Oxidative phosphorylation (NES = 2.7160), fatty acid metabolism (NES = 2.0731), adipogenesis (NES = 1.73), and bile acid metabolism (NES = 1.71) were among the top enriched hallmark pathways. In KEGG gene sets, oxidative phosphorylation, the ribosomal pathway, carbon metabolism, and glyoxylate metabolism were significantly upregulated. Oncogenic signature analysis also highlighted E2F3 transcriptional pathways, STK33-associated signatures, and NRF2-oxidative stress response pathways. This suggests that MMP dysregulation in OSCC is not merely about ECM degradation — it is coupled to enhanced energy production, biosynthetic support for tissue remodeling, and proliferation-related signaling that together drive tumor progression.

The team then turned to survival modeling using Cox proportional hazards regression on the TCGA cohort, which provided the most comprehensive clinicopathological data. Univariate analysis revealed that tumor location, tobacco use, TNM stage III-IV, T stage, and N stage were significantly associated with survival. However, after adjusting for confounders in multivariate Cox regression, only tumor location remained an independent prognostic factor (HR = 1.787, 95% CI = 1.097–2.912, p = 0.0198). Interestingly, none of the six individual MMPs emerged as statistically significant independent prognostic factors on their own — a finding that underscores the complexity of cancer prognosis and the limitations of single-gene biomarkers.

But when the researchers combined the six-MMP expression signature with the conventional TNM staging system, predictive accuracy improved. The standalone MMP signature model achieved a concordance index (C-index) of 0.552, the TNM stage model 0.585, and the integrated combination model 0.609. The area under the ROC curve (AUC) for the combined model reached 0.63, compared to 0.58 for the MMP signature alone and 0.57 for TNM staging alone. Kaplan-Meier survival analysis showed that patients stratified into high-risk groups using the median MMP-based risk score had significantly reduced survival probability (p = 0.045), while TNM staging alone showed only borderline significance (p = 0.088). A nomogram integrating the MMP signature with TNM staging yielded AUC values of 0.655 for 3-year survival and 0.612 for 5-year survival, with calibration graphs confirming strong consistency between predicted and observed outcomes.

The most compelling part of the study came next: clinical validation. The team recruited 170 participants from the Department of Surgical Oncology at Government Royapettah Hospital in Chennai — 79 histologically confirmed, treatment-naive OSCC patients and 91 age- and ethnicity-matched healthy controls. From the six computationally identified MMPs, they prioritized MMP-1, MMP-10, and MMP-9 for serum validation based on their consistent cross-dataset manifestation and documented roles in ECM remodeling and oral tumor invasion. Using sandwich ELISA kits from CUSABIO, they quantified serum protein concentrations and found dramatic elevations in OSCC patients. Median serum MMP-1 was 19.70 ng/mL in OSCC versus 4.290 ng/mL in controls (p < 0.0001). Median serum MMP-10 was 1141 pg/mL in OSCC versus 259.5 pg/mL in controls (p < 0.0001). Median serum MMP-9 was 3.311 ng/mL in OSCC versus 2.379 ng/mL in controls (p = 0.0002). All three comparisons were highly statistically significant.

ROC curve analysis further demonstrated the diagnostic potential of these serum biomarkers. MMP-10 yielded the highest AUC at 0.8843, followed by MMP-1 at 0.8614 and MMP-9 at 0.6653. An AUC above 0.85 is generally considered excellent discrimination between diseased and healthy populations, placing MMP-1 and MMP-10 in that category. The OSCC cohort was predominantly male (74.68%), aged 35–54 (69.6%), with buccal mucosa as the most common tumor site (81.01%), and a striking 87.34% had a history of tobacco usage including cigarette smoking and betel nut chewing — reflecting the lifestyle-related risk factors driving OSCC incidence in South India.

The implications are significant for a region where oral cancer accounts for 55.6% of global cases and 56.5% of related deaths, with India alone representing 85.6% of OSCC incidence among medium-human-development-index nations. Healthcare disparities and delayed diagnosis remain major contributors to advanced-stage presentation and high mortality. A minimally invasive blood test measuring serum MMP-1, MMP-10, and MMP-9 could complement existing screening approaches, particularly in resource-constrained settings where tissue biopsies and imaging may not be readily accessible. The researchers emphasize that these biomarkers are intended as adjuncts to — not replacements for — conventional clinicopathological staging, and that the modest concordance values of the combined prognostic model indicate the need for further validation in larger, multicentre cohorts.

Limitations remain. The computational approach relied on retrospective gene expression data from public repositories, which may introduce population-related bias and dataset heterogeneity. The TCGA cohort may not fully represent the South Indian OSCC population. Serum validation was performed for only three of the six candidate MMPs, and the lack of matched tissue samples prevented tissue-level validation. The study evaluated diagnostic potential rather than therapeutic efficacy. Nevertheless, this is the first study to integrate computational prediction with experimental validation of MMPs as biomarkers in South Indian OSCC patients, and it adds to growing evidence from Iranian, Taiwanese, Indian, Egyptian, and American cohorts linking elevated MMP protein concentrations to oral tumor progression. As the search for early-detection tools for one of Asia’s deadliest cancers intensifies, these zinc-dependent molecular scissors — floating freely in patient serum — may prove to be exactly the minimally invasive window clinicians have been looking for.

Subject of Research: MMP biomarkers for oral squamous cell carcinoma

Article Title: Profiling the MMP family genes as prognostic biomarkers in oral squamous cell carcinoma: from computational discovery to clinical validation in a South Indian cohort

Article References: Sakthi Subhashini, P., Bharanidharan, T., Suresh Kumar, D., & Asha Devi, S. (2026). Profiling the MMP family genes as prognostic biomarkers in oral squamous cell carcinoma: from computational discovery to clinical validation in a South Indian cohort. Frontiers in Bioinformatics, 6, Article 1955795. https://doi.org/10.3389/fbinf.2026.1955795

Image Credits: AI Generated

DOI: 10.3389/fbinf.2026.1955795

Keywords: oral cancer, OSCC, MMP, biomarkers, ELISA, bioinformatics, South India, serum biomarkers, prognosis, early detection, Profiling, family

A major obstacle to accurate CCHF diagnosis is the absence of a universally recognised gold standard serological test. The reference standard for antibody detection requires neutralisation assays, which must be performed in biosafety level 4 (BSL-4) laboratories. These facilities are scarce and largely unavailable in sub-Saharan Africa, including Tanzania, where CCHFV is endemic. Although several commercial molecular and serological diagnostic tests are available, including nucleic acid amplification tests such as reverse transcriptase polymerase chain reaction and loop-mediated isothermal amplification, these approaches face challenges due to substantial genetic variation among viral lineages. Antibody-based serological assays are generally less impacted by genetic variation but have limitations such as delayed antibody response, cross-reactivity, and inability to distinguish recent from past infection. Neutralisation assays are also of limited diagnostic utility for CCHF because the virus elicits low levels of neutralising antibody.

Against this backdrop, a research team led by Elichilia R. Shao of Kilimanjaro Christian Medical Center and the Kilimanjaro Clinical Research Institute in Moshi, Tanzania, together with collaborators from institutions including the University of Glasgow, Duke University, Washington State University, and Duke-National University of Singapore Medical School, conducted a study to evaluate the diagnostic performance of two serological assays for detecting prior CCHFV exposure in humans. The work, published in Frontiers in Microbiology, employed a Bayesian latent class modelling approach in the absence of a reference standard, allowing simultaneous estimation of test sensitivity, specificity, and true seroprevalence without relying on a gold standard.

The study was a secondary analysis of archived serum samples from a prospective febrile illness surveillance cohort conducted between 2012 and 2014 in Moshi, Tanzania, at Kilimanjaro Christian Medical Centre (KCMC) and Mawenzi Regional Referral Hospital (MRRH). At the time, KCMC was a 450-bed zonal referral and teaching hospital serving more than 15 million people in northern Tanzania, while MRRH, five kilometres away, was a 300-bed referral hospital for the Kilimanjaro Region. Of 870 febrile admissions enrolled across both sites, serum samples were available for 427 participants, representing 49 percent of the cohort. Participants were classified as livestock owners if their household owned one or more livestock species, including cattle, sheep, goats, pigs, poultry, camels, or horses, and as non-livestock owners otherwise. Of the 427 participants with available serum, 147 were livestock owners and 280 were non-livestock owners.

Two assays were compared. The first was the commercial ID Screen CCHF double-antigen multi-species enzyme-linked immunosorbent assay (ELISA) kit from IDvet Innovative Diagnostics, France, which detects IgG antibodies to the CCHFV nucleocapsid protein (NP). In this assay, test sera were diluted and incubated at 25 degrees Celsius for 45 minutes, followed by conjugate and substrate steps at 25 degrees Celsius for 30 and 15 minutes respectively. Absorbance was measured at 450 nanometres using an automated ELISA reader, and samples were deemed positive if their sample positivity percentage exceeded 30 percent. The second was a laboratory-developed microsphere immunoassay using Luminex technology, a qualitative multiplex magnetic bead-based assay in which virus-specific microsphere sets enabled simultaneous detection of NP-targeted IgG in a single well, relying on fluorescence and flow cytometry principles.

The analytical framework was based on the Hui-Walter Bayesian latent class model, a statistical framework for assessing diagnostic test accuracy when true disease status is uncertain. Three key assumptions underpin this model. First, the sensitivity and specificity of each test are considered constant across the subpopulations studied. The researchers considered this assumption not violated because livestock keepers and non-livestock keepers were from the same geographic area with broadly similar demographic and environmental conditions. Second, diagnostic tests have the same performance across subpopulations despite differences in seroprevalence, which was supported by standardised protocols for sample collection and assay implementation, and by laboratory personnel being blinded to subpopulation status. Third, conditional independence is presumed, where tests are independent given true disease status. However, because both assays measure the same underlying biological process, host antibodies to CCHFV antigens, their results are likely correlated even after accounting for true infection status. The model was therefore extended to incorporate conditional dependence using a covariance parameterisation.

Prior distributions were informed by a literature review covering peer-reviewed articles published from January 2018 to December 2025, with emphasis on East African studies. Sensitivity and specificity priors assumed beta distributions. For the Luminex sensitivity, no literature was identified, so the final model specified the Luminex sensitivity prior the same as the IDvet prior, given the comparable serological detection principles of the two assays. Seroprevalence priors were guided by East African CCHFV seroprevalence estimates ranging from 1.8 to 19 percent, using an informative beta distribution with a prior mean of 9.1 percent. The model was implemented in Just Another Gibbs Sampler (JAGS) using the rjags package in R, with three chains, a burn-in phase of 10,000 iterations, and 6,000 sampling iterations thinned by 10, resulting in 1,800 posterior samples. Convergence was assessed with the Gelman-Rubin diagnostic, the Heidelberger-Welch stationarity test, trace plots, and effective sample size checks.

The results demonstrated high diagnostic performance for both assays. The median posterior estimate for IDvet sensitivity was 0.893 with a 95 percent Bayesian credibility interval (BCI) of 0.555 to 0.996, and specificity was 0.972 with a 95 percent BCI of 0.936 to 0.996. For the Luminex assay, the median posterior sensitivity estimate was 0.884 with a 95 percent BCI of 0.541 to 0.995, and specificity was 0.987 with a 95 percent BCI of 0.947 to 1.00. The model generated seroprevalence estimates for the two subpopulations. The livestock owner seroprevalence estimate was 0.027 with a 95 percent BCI of 0.002 to 0.069, while for non-livestock owners it was 0.017 with a 95 percent BCI of 0.001 to 0.044. Crude seroprevalence was 4.0 percent by IDvet and 2.3 percent by Luminex across all participants. Both assays showed very high negative predictive values exceeding 0.99 across all groups, while positive predictive values were lower, particularly for IDvet, with Luminex showing higher PPV among non-livestock owners consistent with its higher specificity.

The slightly higher seroprevalence among livestock owners might be explained by the age difference among livestock owners, who were slightly older, meaning more years of potential cumulative occupational and environmental exposure. The presence of seropositive individuals among non-livestock owners suggests that CCHFV exposure extends beyond groups with close livestock links typically considered at high risk. Possible explanations include environmental exposure to infected ticks, handling of contaminated animal products outside the home, or other unrecognised community pathways. Alternatively, reports of livestock ownership may not correlate with livestock contact-related activities such as milking or assisting deliveries. The covariance parameters for exposed and non-exposed individuals were centred near zero, with credibility intervals encompassing zero, indicating limited residual dependence between the two assays after adjusting for infection status.

The findings carry practical implications for CCHFV surveillance in endemic regions lacking reference-standard testing. Both platforms are suitable for CCHFV serosurveillance and epidemiological investigations, with the IDvet ELISA offering operational advantages because of its simplicity and suitability for decentralised laboratories, while the Luminex platform may offer additional value in specialised reference laboratories and research applications. At the country level, the IDvet can be used by the Tanzania Veterinary Laboratory Agency and human health facilities in tandem to provide a unified data stream for national CCHF preparedness and outbreak response. Several limitations should be acknowledged, including the relatively small number of seropositive samples leading to wide credibility intervals particularly for sensitivity and seroprevalence estimates, the measurement of IgG antibodies reflecting prior exposure rather than acute infection, prior distributions informed by a limited number of published diagnostic studies, and the use of archived sera collected in 2012 to 2014. Future studies with larger sample sizes, molecular confirmation, and evaluation across diverse endemic populations will be important for refining diagnostic performance estimates and supporting harmonisation of CCHFV serological testing strategies.

Subject of Research: Virology

Article Title: Comparison of two Crimean-Congo haemorrhagic fever virus serological tests in Tanzanian febrile patients using a Bayesian latent class approach

Article References: Shao, E. R., Bodenham, R. F., Chilongola, J., Cleaveland, S., Maro, V. P., Mujaga, B., Mlay, E. A., Shirima, L. J., Pyuza, J. J., Njau, J., Lankester, F., Kayaga, R., Rubach, M. P., Crump, J. A., Tan, C. W., Wang, L.-F., Rostal, M. K., & Mmbaga, B. T. (2026). Comparison of two Crimean-Congo haemorrhagic fever virus serological tests in Tanzanian febrile patients using a Bayesian latent class approach. Frontiers in Microbiology, 17, Article 1894712. https://doi.org/10.3389/fmicb.2026.1894712

Image Credits: AI Generated

DOI: 10.3389/fmicb.2026.1894712

Keywords: Crimean-Congo haemorrhagic fever virus, CCHFV, serology, Bayesian latent class model, diagnostic accuracy, ELISA, Luminex, Tanzania, febrile illness, zoonoses, Comparison, Crimean-Congo

The research team, led by scientists at the University of Asia Pacific and BRAC University in Dhaka, recruited 44 patients diagnosed with generalized anxiety disorder and 44 age- and sex-matched healthy controls. A professional psychiatrist evaluated all participants against DSM-5 criteria, and symptom severity was quantified using the widely used 7-item Generalized Anxiety Disorder scale, or GAD-7, which scores anxiety from minimal to severe on a 0-to-21 range. The researchers deliberately excluded anyone with other psychiatric conditions, chronic liver or kidney disease, acute or chronic infections, cancer, autoimmune disorders, recent use of anxiolytic or antidepressant medication, or pregnancy, because each of these factors could independently distort circulating cytokine levels and muddy the comparison.

Blood samples were drawn from each participant, allowed to clot, centrifuged to separate the serum, and stored at minus 80 degrees Celsius until analysis. The team then quantified interleukin-4 and MCP-3 concentrations using enzyme-linked immunosorbent assays, a standard laboratory technique in which antibodies capture the target molecule from the sample and a colorimetric reaction, read at 450 nanometers, reveals how much of it is present. Concentrations were calculated against standard curves and expressed in picograms per milliliter. Statistical comparisons relied on t-tests, chi-square tests for categorical data, Spearman correlation analysis, and receiver operating characteristic curve analysis to test how well each molecule could distinguish patients from controls.

The results were striking. Patients with generalized anxiety disorder had serum interleukin-4 concentrations averaging 11.82 picograms per milliliter, less than half the 24.51 picograms per milliliter measured in healthy controls. MCP-3 moved in the opposite direction, averaging 57.80 picograms per milliliter in patients versus 34.01 in controls. Both differences were highly statistically significant, with p-values below 0.001. Crucially, the two molecules also tracked symptom severity: interleukin-4 levels correlated negatively with GAD-7 scores, with a correlation coefficient of minus 0.496, while MCP-3 correlated positively with a coefficient of 0.544. In other words, the more severe the anxiety, the lower the anti-inflammatory signal and the higher the pro-inflammatory one.

Interleukin-4 is a cytokine produced primarily by Th2 helper T cells, and it acts as a molecular brake on inflammation. It suppresses the production of inflammatory mediators such as interleukin-1, interleukin-6, tumor necrosis factor-alpha, interleukin-8, and MCP-3 itself, while boosting natural anti-inflammatory regulators like the interleukin-1 receptor antagonist. In the brain, interleukin-4 has a well-documented neuroprotective role: it nudges resident immune cells called microglia away from the classically activated M1 state, which pumps out pro-inflammatory cytokines, and toward the alternatively activated M2 state, which releases anti-inflammatory molecules such as TGF-beta and interleukin-10 and helps resolve tissue damage. Animal studies have shown that this M1-to-M2 switching, mediated through the JAK1/STAT6 signaling pathway, protects the brain after injury. A deficit of interleukin-4, the authors argue, could therefore remove a key counterweight to neuroinflammation in brain regions that govern fear and worry.

MCP-3, by contrast, belongs to the CC chemokine family, a group of signaling proteins that guide immune cells to sites of inflammation through a process called chemotaxis. Structurally and functionally similar to its better-known cousin MCP-1, MCP-3 is a potent attractant for monocytes, T cells, natural killer cells, basophils, eosinophils, and dendritic cells. It exerts these effects by binding to the CCR2 receptor, found abundantly on monocytes and activated lymphocytes, and also to the CCR1 receptor. Studies in genetically engineered mice lacking MCP-3 have confirmed that the chemokine is a key driver of monocyte recruitment to inflamed tissue. Elevated MCP-3 in anxiety patients thus suggests an active mobilization of inflammatory cells, consistent with the hypothesis that chronic low-grade inflammation feeds into the biology of persistent worry.

The diagnostic potential of the two molecules was assessed with receiver operating characteristic analysis, which plots sensitivity against specificity across different cutoff values. MCP-3 emerged as the stronger performer, achieving an area under the curve of 0.848, with 87.6 percent sensitivity and 84.3 percent specificity at a cutoff of 45.0 picograms per milliliter. Interleukin-4 performed respectably but less impressively, with an area under the curve of 0.782, 80.2 percent sensitivity, and 78.5 percent specificity at a cutoff of 15.0 picograms per milliliter. An area under the curve approaching 0.85 is generally considered good discrimination, meaning a single blood test for MCP-3 could potentially flag a substantial majority of true anxiety cases while correctly clearing most healthy people, though it would not replace clinical assessment on its own.

The findings fit within a broader and sometimes contradictory literature. Preclinical work has repeatedly shown that injecting pro-inflammatory cytokines such as interleukin-1beta, interleukin-6, or tumor necrosis factor-alpha into animals induces anxiety-like behavior, and that this effect can be reversed by anti-inflammatory cytokines like interleukin-4 and interleukin-10. Clinical studies have often reported elevated pro-inflammatory and reduced anti-inflammatory cytokines in anxious patients, although some studies have found no differences or even lowered pro-inflammatory signals, highlighting how inconsistent the field remains. The cytokine hypothesis of anxiety proposes that pro-inflammatory molecules reduce serotonin production or increase its reuptake, thereby disturbing the serotonergic signaling that current medications like selective serotonin reuptake inhibitors are designed to enhance. Notably, roughly half of patients with generalized anxiety disorder do not respond adequately to existing drugs, and symptoms recur in at least 30 percent, underscoring the need for new mechanistic angles.

The study’s authors also see therapeutic potential in the interleukin-4/MCP-3 axis. Anti-cytokine monoclonal antibodies are already transforming the treatment of autoimmune diseases: secukinumab, ixekizumab, and bimekizumab block interleukin-17A, while ustekinumab targets interleukin-23A, and these agents are used in inflammatory bowel disease, psoriatic arthritis, and rheumatoid arthritis. If the same logic applies to anxiety, drugs that restore interleukin-4 signaling or dampen MCP-3-driven monocyte recruitment could one day complement or improve upon existing anxiolytics. The authors caution, however, that the immune system is finely balanced and that any such approach would require a deep understanding of which immune processes actually drive the disorder rather than merely accompany it.

Important limitations temper the excitement. The sample of 88 participants is small and drawn from a single Bangladeshi clinical setting, so the results may not generalize to other populations. As a case-control design, the study can demonstrate association but not causation; it remains unclear whether immune dysregulation contributes to causing anxiety, whether anxiety itself alters immune function, or whether both are driven by a third factor. The researchers also lacked detailed records of psychopharmacological treatment, and since antidepressants can themselves modulate inflammatory pathways, this absence may have confounded the observed associations. Sociodemographic differences in economic status and family history between the groups further complicate interpretation. The authors call for longitudinal studies with comprehensive medication histories to clarify the temporal dynamics of immune dysregulation as generalized anxiety disorder develops and progresses. Until then, the study stands as a compelling piece of evidence that the blood carries echoes of the anxious mind, and that measuring those echoes may one day help clinicians detect, grade, and treat one of the world’s most burdensome psychiatric conditions.

Subject of Research: Association of serum interleukin-4 and monocyte chemoattractant protein-3 levels with generalized anxiety disorder

Article Title: Altered serum interleukin-4 and monocyte chemoattractant protein-3 levels are associated with generalized anxiety disorder: a case-control study

Article References: Binta Rashid, M. H., Islam, M., Ashraful Islam, S. M., & Islam, M. R. (2026). Altered serum interleukin-4 and monocyte chemoattractant protein-3 levels are associated with generalized anxiety disorder: a case-control study. Experimental Biology and Medicine, 251, Article 11144. https://doi.org/10.3389/ebm.2026.11144

Image Credits: AI Generated

DOI: 10.3389/ebm.2026.11144

Keywords: generalized anxiety disorder, interleukin-4, MCP-3, cytokines, neuroinflammation, biomarkers, ELISA, ROC analysis, immune dysregulation, case-control study, microglia, anxiety severity

The new assay, described in Frontiers in Allergy by researchers from EPS Holdings, EPS Innovative Medicine, Intelligence and Technology Lab, and Wakayama Medical University, focuses on a molecule called secretory immunoglobulin A, or SIgA. Unlike the antibodies circulating in blood, SIgA is the workhorse of the body’s mucosal defenses, guarding the wet surfaces of the mouth, nose, and gut. Structurally, SIgA is polymeric—mainly dimeric—and is complexed with a secretory component that shields its enzymatically vulnerable regions. This molecular armor makes SIgA remarkably stable in harsh environments where other antibodies would be degraded. Because SIgA plays a central role in immune tolerance toward commensal bacteria and dietary antigens, allergen-specific SIgA in saliva has long been suspected to be a promising biomarker for judging whether sublingual immunotherapy is taking hold.

There has, however, been a stubborn technical obstacle standing in the way. Saliva is a notoriously difficult fluid for immunoassays. It teems with bacteria and other microorganisms that are physiologically absent from blood, and it contains abundant lytic enzymes, including matrix metalloproteases and lysozymes, that can degrade immunoglobulins and even attack the reagents of the assay itself. These components can alter the conformation of proteins or generate neo-antigens, producing non-specific binding and a high background noise that drowns out the true signal. In previous studies measuring antigen-specific SIgA in saliva, samples had to be assayed at low dilutions—typically up to 1:160, and between 1:2 and 1:160 in studies of salivary antibodies against SARS-CoV-2. Low dilutions mean more interfering material and therefore more background, which limits sensitivity and makes small changes in antibody levels nearly impossible to detect.

The research team’s solution combines two clever engineering choices. First, they adopted a signal amplification chemistry known as catalyzed reporter deposition, originally reported by Bobrow and colleagues, which uses biotinyl-tyramide, or BT-Tyr. In this scheme, horseradish peroxidase serves a double role, acting both as a reporter enzyme and as the catalyst for amplification. After the peroxidase-labeled reagent is immobilized in the ELISA well, BT-Tyr is added together with a trace amount of hydrogen peroxide. The enzyme converts the biotinylated phenolic compound into reactive free radicals that deposit covalently onto electron-rich moieties—tyrosine and tryptophan residues—of the blocking protein coating the well. A second dose of streptavidin-conjugated peroxidase then binds the deposited biotin, creating a clump of reporter signal. Crucially, the degree of amplification correlates with the amount of analyte originally present, so quantitativeness is preserved rather than sacrificed.

The second choice addressed specificity. Instead of detecting SIgA with a labeled anti-IgA antibody, the researchers biotinylated the allergen itself and used it as the reporter. The target allergen was Sugi basic protein, the principal antigen complex of Japanese cedar pollen, comprising the major antigens Cry j1 and Cry j2. In an absorption test designed to prove specificity, pooled saliva diluted 1:400 was preincubated with free SBP before assay. When biotinylated SBP served as the reporter in antibody-coated wells, preincubation with SBP at just 0.8 micrograms per milliliter was enough to absorb the specific SIgA and abolish the signal. In contrast, when a biotinylated anti-IgA antibody was used as the reporter in antigen-coated wells, the blocking effect never exceeded 80 percent even at 4 micrograms per milliliter, because non-specific binding of saliva components interfered. The biotinylated-antigen reporter approach was clearly superior.

Sensitivity figures were equally striking. Compared with a non-amplified version of the assay, the BT-Tyr-amplified method delivered more than 200-fold signal amplification. The limit of detection—defined as the blank mean plus three standard deviations—was 0.104 absorbance units for the amplified assay versus 0.039 for the non-amplified version, and raw readings from a saliva sample diluted 12,000-fold still rose above the detection threshold. Blocking chemistry mattered here too: sodium casein outperformed bovine serum albumin as a blocking agent, yielding blank absorbance of roughly 0.041 compared with 0.143 for BSA, thanks to the heterogeneous, small-sized casein proteins that blanket the plate surface efficiently without obscuring the immobilized capture antibodies.

With the assay validated, the team turned to the clinic. Twenty-two patients with Japanese cedar pollinosis receiving sublingual immunotherapy with CEDARCURE tablets—2,000 JAU daily for the first week, then 5,000 JAU daily—along with five untreated patients, provided saliva samples at three-month intervals over twelve months. Each sample was diluted just 1:450, a dilution far higher than conventional assays could tolerate. The results revealed clear individual differences. Defining a responder as a patient whose salivary SBP-specific SIgA exceeded an absorbance of 0.2 at any time point, eleven of the sixteen analyzed immunotherapy patients—69 percent—qualified as mucosal immune responders, while five, or 31 percent, never crossed the threshold and were classified as non-responders. None of the untreated patients showed any increase; their absorbance values never exceeded 0.2 throughout the study.

The timing of the immune response was perhaps the most clinically meaningful finding. Among responders, salivary SBP-specific SIgA levels rose significantly by nine months after starting treatment at the latest, and the differences were statistically robust: at the nine-month point, responders differed from non-responders with p = 0.002 and from untreated patients with p = 0.036; at twelve months, the corresponding values were p = 0.0004 and p = 0.0014. In practical terms, this means that within roughly three-quarters of a year—a fraction of the typical multi-year immunotherapy course—patients and physicians could, in principle, obtain an objective reading of whether the mucosal immune system is mounting the desired response, rather than waiting for pollen seasons to pass and symptoms to (or not to) fade.

The researchers are careful about the limits of their preliminary study. The sample size was small, and larger cohorts will be needed for definitive statistical evaluation. They also note that a standardized arbitrary unit, built from a standard curve generated by serially diluting a high-titer saliva sample, will be required to minimize variation between assays, and that future work must test whether rising SIgA levels actually correlate with symptom improvement. Yet the practical advantages of the platform are considerable. All reagents are commercially available, and readout requires only a conventional chromogenic plate reader measuring absorbance at 450 nanometers—far cheaper and more widely accessible than fluorescence or chemiluminescence instruments. And because most allergens are proteins that can be biotinylated with standard labeling kits, the same amplified format could be adapted to monitor immunity against virtually any allergen, giving clinicians a versatile new window onto the mucosal immune system and, potentially, an early warning system for patients who are not responding to treatment.

Subject of Research: A sensitive amplified ELISA for measuring allergen-specific salivary secretory IgA to monitor sublingual immunotherapy efficacy in Japanese cedar pollinosis

Article Title: A sensitive colorimetric ELISA to measure allergen-specific salivary SIgA for monitoring sublingual immunity efficiency in pollinosis SLIT

Article References: Yamamoto, T., Mitsunaga, F., Kotani, A., Tajima, K., Hotomi, M., & Nakamura, S. (2026). A sensitive colorimetric ELISA to measure allergen-specific salivary SIgA for monitoring sublingual immunity efficiency in pollinosis SLIT. Frontiers in Allergy, 7, Article 1857343. https://doi.org/10.3389/falgy.2026.1857343

Image Credits: AI Generated

DOI: 10.3389/falgy.2026.1857343

Keywords: sublingual immunotherapy, ELISA, secretory IgA, saliva, Japanese cedar pollinosis, biotinyl-tyramide, signal amplification, allergen-specific antibodies, Sugi basic protein, mucosal immunity, allergy biomarker, Frontiers in Allergy

The study focused on MRC-5 cells, a widely used line of human lung fibroblasts. Fibroblasts are the unsung architects of the lung: they spin out the collagen, elastin, and other structural proteins that form the extracellular matrix, the three-dimensional scaffold that gives tissue its shape and elasticity. In the lung, this matrix is far more than passive scaffolding. It actively regulates development, repair, and cellular behavior, and its disorganization is a hallmark of chronic diseases ranging from chronic obstructive pulmonary disease to pulmonary fibrosis. Because resident fibroblasts are the principal matrix-producing cells of the lung interstitium, they are an ideal testing ground for compounds that might tip the balance of matrix maintenance in a favorable direction.

Before probing biomarkers, the researchers had to establish a safe dose. Using the XTT colorimetric assay, they exposed MRC-5 cells to EAA concentrations ranging from 1.25 to 160 millimolar for 24 and 48 hours. At low concentrations of 1.25 to 5 millimolar, viability after 24 hours actually exceeded control levels by 10 to 20 percent, hinting at a mild proliferative stimulus, though this effect faded toward baseline by 48 hours. Intermediate concentrations of 10 to 20 millimolar trimmed viability by roughly 10 to 25 percent, and concentrations of 40 millimolar or higher proved clearly cytotoxic. The team therefore settled on 5 millimolar for all subsequent experiments, a dose that preserved viability at or slightly above control levels across both exposure periods.

With a non-toxic dose in hand, the researchers turned to enzyme-linked immunosorbent assays, or ELISAs, to quantify a panel of nine proteins secreted into the culture medium: three pro-inflammatory cytokines, three matrix-building components, and three matrix-degrading enzymes. The inflammatory results were the first surprise. Under completely unstimulated, basal conditions, EAA treatment significantly lowered interleukin-1 beta by approximately 3 to 4 percent, interleukin-6 by about 26 percent, and tumor necrosis factor-alpha by roughly 24 percent, with p-values of 0.024, 0.013, and 0.006 respectively. These cytokines are not merely markers of inflammation; they actively drive the production of matrix-degrading enzymes, so damping them down could, in principle, protect the lung’s structural framework from inflammatory erosion.

The matrix-building side of the ledger told an even more dramatic story. Levels of collagen type I and collagen type III, the two fibrillar collagens that provide tensile strength to connective tissue, rose significantly in EAA-treated cells at both 24 and 48 hours, and the effect grew stronger with time. Two-way analysis of variance revealed highly significant effects of treatment, time, and their interaction for both collagen types, all with p-values below 0.0001. By 48 hours, EAA-treated cultures showed the highest collagen levels of any group. This is biochemically coherent: vitamin C serves as an essential cofactor for prolyl and lysyl hydroxylases, the enzymes that stitch together the hydroxylated residues needed to stabilize the collagen triple helix, and decades of prior work have shown that ascorbate stimulates collagen synthesis in fibroblasts, with maximal production typically emerging after about two days of exposure.

Just as notable was the behavior of hyaluronan synthase 2, or HAS2, the enzyme responsible for manufacturing hyaluronic acid, the glycosaminoglycan that keeps tissue hydrated, elastic, and communicative. HAS2 levels climbed significantly in EAA-treated cells at both time points, with the largest increase again at 48 hours and all pairwise comparisons against controls reaching p-values below 0.0001. The finding echoes earlier reports that ascorbic acid stimulates hyaluronic acid production in human trabecular meshwork cells, but extending that effect to lung fibroblasts through a stable derivative is new. Together, the collagen and HAS2 data suggest that EAA nudges fibroblasts toward a more matrix-productive state rather than simply acting as a passive antioxidant.

The matrix-degrading enzymes added a layer of nuance that makes the study genuinely interesting. Matrix metalloproteinase-1, which cleaves fibrillar collagens, and matrix metalloproteinase-9, which degrades a broader slate of matrix components, both responded to EAA in a biphasic, time-dependent fashion: their levels were higher than controls at 24 hours but lower than controls at 48 hours. For MMP-9, the two-way ANOVA showed significant effects of treatment, time, and interaction, while for MMP-1 the interaction was significant even though the overall treatment effect was not, indicating that EAA reshaped the enzyme’s trajectory over time rather than pushing it uniformly up or down. The authors suggest this early rise may reflect the dynamic sequence seen during tissue remodeling, in which a transient wave of matrix degradation precedes a phase of renewed synthesis.

Elastase, by contrast, showed no such ambivalence. This protease, best known as a weapon of neutrophils but also produced by fibroblasts themselves, chews through elastin and has been implicated in wrinkle formation in skin and in progressive structural deterioration in the lung. EAA reduced elastase levels at both 24 and 48 hours, with a significant main effect of treatment at p below 0.0001 and confirmed pairwise reductions at both time points. Because elastase-driven destruction of elastic fibers is a recurring theme in emphysema and other pulmonary disorders, a compound that consistently suppresses fibroblast-derived elastase while simultaneously raising collagen and hyaluronic acid machinery paints an intriguing picture of a cellular environment tilted toward matrix preservation.

Taken together, the measured biomarkers shifted in a coherent direction: less inflammatory signaling, more matrix-building output, and, by the later time point, less matrix-degrading capacity. The authors are careful, however, to keep the interpretation provisional. The experiments were conducted in a single fibroblast cell line under in vitro conditions, without an inflammatory stimulus, so the cytokine reductions reflect modulation of constitutive signaling rather than suppression of an induced inflammatory response. The study measured protein levels in culture supernatants, not protease activity, collagen deposition or cross-linking, actual hyaluronan production, or functional matrix remodeling. And because native L-ascorbic acid was not included as a comparator, the results cannot say whether EAA outperforms ordinary vitamin C or merely reproduces its effects in a more stable package.

Those caveats define the roadmap for what comes next. Side-by-side comparisons with L-ascorbic acid and other stable derivatives such as 2-phospho-L-ascorbate would clarify EAA’s relative potency, while experiments using inflammatory stimuli, co-culture systems, or three-dimensional lung tissue models would test whether the biomarker shifts translate into genuine functional changes in matrix homeostasis. Still, the core finding stands on its own: a cosmetic-industry favorite, long valued mainly for its shelf stability, turns out to be an active modulator of inflammatory and structural biology in human lung fibroblasts. If follow-up work confirms that these biomarker changes reflect real matrix remodeling, EAA could move from the skincare aisle toward a role in protecting the lung’s delicate architectural scaffold against the slow degradation that underlies so many chronic respiratory diseases.

Subject of Research: Effects of 3-O-ethyl-L-ascorbic acid on inflammatory and extracellular matrix biomarkers in human lung fibroblasts

Article Title: 3-O-ethyl-L-ascorbic acid modulates pro-inflammatory cytokine and extracellular matrix-related biomarker levels in human lung fibroblasts: an in vitro study

Article References: Türkan, A., Türkoğlu, M., Öncü, G., & Sevinç, H. (2026). 3-O-ethyl-L-ascorbic acid modulates pro-inflammatory cytokine and extracellular matrix-related biomarker levels in human lung fibroblasts: an in vitro study. Acta Biochimica Polonica, 73, Article 16774. https://doi.org/10.3389/abp.2026.16774

Image Credits: AI Generated

DOI: 10.3389/abp.2026.16774

Keywords: 3-O-ethyl-L-ascorbic acid, vitamin C, MRC-5 fibroblasts, extracellular matrix, collagen, hyaluronan synthase 2, matrix metalloproteinases, elastase, interleukin-6, TNF-alpha, lung fibrosis, ELISA